Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2024 09:20 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
August 13, 2024 08:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills...
August 08, 2024 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....
July 30, 2024 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma, Inc. Announces Reverse Stock Split

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
June 17, 2024 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...
May 16, 2024 16:02 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
May 14, 2024 16:15 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2024 Financial Results

114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif.,...
April 17, 2024 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
March 21, 2024 16:15 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
March 14, 2024 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 ...